Processa Pharmaceuticals Inc (NASDAQ:PCSA) has a beta value of 1.31 and has seen 44.44 million shares traded in the recent trading session. The company, currently valued at $1.73M, closed the recent trade at $0.33 per share which meant it lost -$0.08 on the day or -20.27% during that session. The PCSA stock price is -903.03% off its 52-week high price of $3.31 and -9.09% below the 52-week low of $0.36. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.16 million shares traded. The 3-month trading volume is 235.72K shares.
The consensus among analysts is that Processa Pharmaceuticals Inc (PCSA) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.77.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
Sporting -20.27% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PCSA stock price touched $0.33 or saw a rise of 32.35%. Year-to-date, Processa Pharmaceuticals Inc shares have moved -62.83%, while the 5-day performance has seen it change -16.11%. Over the past 30 days, the shares of Processa Pharmaceuticals Inc (NASDAQ:PCSA) have changed -33.00%. Short interest in the company has seen 95265.0 shares shorted with days to cover at 0.93.
Wall Street analysts have a consensus price target for the stock at $9, which means that the shares’ value could jump 96.33% from the levels at last check today. The projected low price target is $9.0 while the price target rests at a high of $9.0. In that case, then, we find that the latest price level in today’s session is -2627.27% off the targeted high while a plunge would see the stock gain -2627.27% from the levels at last check today.
Processa Pharmaceuticals Inc (PCSA) estimates and forecasts
The company’s shares have lost -76.02% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.65% over the past 5 years. Earnings growth for 2025 is a modest 75.19% while over the next 5 years, the company’s earnings are expected to increase by 42.65%.
PCSA Dividends
Processa Pharmaceuticals Inc is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders
Insiders own 5.13% of the company shares, while shares held by institutions stand at 1.88% with a share float percentage of 1.98%. Investors are also buoyed by the number of investors in a company, with Processa Pharmaceuticals Inc having a total of 9.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 0.46% shares in the company for having 24.43 shares of worth $8014.0 while later fund manager owns 16.5 shares of worth $5411.0 as of Jan 31, 2025, which makes it owner of about 0.31% of company’s outstanding stock.
